🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise globally, with data suggesting in excess of 82 million infections each year. Notably increased rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs currently available.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This places it at an equal footing with the typical regimen, which uses a dual-drug approach. The research included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed positive views. Access to a one-pill regimen such as this is described as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.